Anticorpos monoclonais para combater toda a família dos betacoronavírus.

Neutralizing monoclonal antibodies against a whole Family of viruses (betacoronavirus).

Independent laboratory founded by experts in immunology, virology, monoclonal antibodies (mAbs) and clinical trials. Our goal is to ameliorate suffering from infectious diseases.

Biotech independente fundada por especialistas em imunologia, virologia, anticorpos monoclonais (mAbs) e ensaios cl&iacute;nicos. Nosso meta &eacute; aliviar o sofrimento causado por doen&ccedil;as infecciosas.

Mabloc

Laboratory

Laboratório

nmAbs contra toda uma família de vírus (betacoronavírus)

This project builds up on lessons learned from the HIV epidemic, in which one virus can differ from another by more than 30%. If bnMAbs can be isolated against the highly variable HIV, then it should be possible to develop bnMAbs against all members of a particular family of viruses.

Este projeto se estrutura a partir de li&ccedil;&otilde;es aprendidas com a epidemia de HIV, na qual observamos que um v&iacute;rus pode diferir de outro em mais de 30%. Se os bnMAbs podem ser isolados contra o HIV altamente vari&aacute;vel, ent&atilde;o deve ser poss&iacute;vel desenvolver bnMAbs contra todos os membros de uma fam&iacute;lia particular de v&iacute;rus.

Deploying clinical trials for broadly neutralizing monoclonal antibodies (bnMAbs) against SARS-CoV-2 and its variants.

Implantação de ensaios clínicos para anticorpos monoclonais amplamente neutralizantes (bnmAbs) contra Sars-CoV-2 e suas variantes.

Old Enemies

Velhos Inimigos

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has ground the world&rsquo;s economy to a halt. However, these epidemics are not new. From Severe Acute Respiratory Syndrome (SARS) in 2003 to Middle East Respiratory Syndrome (MERS), Ebola (EBOV), and Zika virus, viral epidemics have happened with increasing regularity over the last two decades, highlighting the growing importance of this new class of drug in the treatment of infectious disease.

A pandemia de coronav&iacute;rus 2 &ndash; s&iacute;ndrome respirat&oacute;ria aguda grave (SARS-CoV-2) &ndash; parou a economia mundial. No entanto, essas epidemias n&atilde;o s&atilde;o novas. Da S&iacute;ndrome Respirat&oacute;ria Aguda Grave (SARS), que aconteceu em 2003, &agrave; S&iacute;ndrome Respirat&oacute;ria do Oriente M&eacute;dio (MERS), Ebola (EBOV) e Zika v&iacute;rus, epidemias virais aconteceram com crescente regularidade nas &uacute;ltimas duas d&eacute;cadas, destacando a crescente import&acirc;ncia dessa nova classe de medicamento &ndash; os anticorpos monoclonais &ndash; no tratamento de doen&ccedil;as infecciosas.

&nbsp;

Deploying clinical trials for broadly neutralizing monoclonal antibodies (bnmAbs) against Sars-CoV-2 and its variants.

Implantação de ensaios clínicos para anticorpos monoclonais amplamente neutralizantes (bnMAbs) contra SARS-CoV-2 e suas variantes.

New class of drug

Um novo tipo de medicamento

Os surtos recorrentes do vírus da Dengue (DENV) e a recente epidemia do vírus Zika (ZIKV) mostram que continuamos despreparados para controlar os vírus transmitidos por mosquitos.

The recurring outbreaks of Dengue virus (DENV) and the recent Zika virus (ZIKV) epidemic show that we remain unprepared to control mosquito-born viruses.

Prevenção e tratamento de infecções por DENV e ZIKV

Preventing and treating DENV and ZIKV infections

With more than 100 countries affected and more than 3 billion people at risk of DENV and ZIKV infections, the development of safe and efficacious control measures for these viruses are international priorities. Reemergence of DENV and ZIKV in the U.S. is a real possibility, with recent outbreaks of one or both of these viruses reported in Florida, Texas, Hawaii, and Puerto Rico. Developing novel preventive and therapeutic strategies will be essential to limiting complications associated with future epidemics.

Com mais de 100 pa&iacute;ses afetados e mais de 3 bilh&otilde;es de pessoas em risco de infec&ccedil;&otilde;es por Dengue (DENV) e Zika (ZIKV), o desenvolvimento de medidas seguras e eficazes de controle para esses v&iacute;rus &eacute; prioridade internacional. O ressurgimento da DENV e ZIKV nos EUA &eacute; uma possibilidade real, com surtos recentes de um ou ambos os v&iacute;rus relatados na Fl&oacute;rida, Texas, Hava&iacute; e Porto Rico. Desenvolver novas estrat&eacute;gias de terap&ecirc;utica e preven&ccedil;&atilde;o ser&aacute; essencial para limitar as complica&ccedil;&otilde;es associadas a futuras epidemias.

Our long-term goal is to use a cocktail of nMAbs to prevent DENV and ZIKV infection in at-risk populations, thereby reducing virus-induced morbidity, transmission, and the possibility of severe consequences after infection occurs.

Nosso objetivo de longo prazo é usar um coquetel de anticorpos monoclonais (nMAbs) para prevenir a infecção por Dengue (DENV) e Zika (ZIKV) em populações de risco, reduzindo assim a morbidade induzida pelo vírus, a transmissão e a possibilidade de consequências graves após a ocorrência da infecção.

About the project

Novas epidemias

We have already isolated 200 MAbs against DENV and ZIKV, and we have also isolated 100 MAbs from ZIKV-infected individuals that had previously been infected with DENV. Many of these MAbs neutralized ZIKV&mdash;five at very low concentrations. Additionally, we have used a ZIKV-specific cocktail of three mutated neutralizing MAbs&mdash;SMZAb1, SMZAb2, and SMZAb5&mdash;to successfully prevent ZIKV infection in non-human primates. Further experiments demonstrated that one of these MAbs administered on its own, SMZAb2, prevented ZIKV infection.

Read more:&nbsp;<a href="https://www.google.com/url?q=https://www.science.org/doi/10.1126/scitranslmed.aan8184&amp;sa=D&amp;source=docs&amp;ust=1663166385692860&amp;usg=AOvVaw3ov6BVn08bikvrEmhZUT9m">https://www.science.org/doi/10.1126/scitranslmed.aan8184</a>

J&aacute; isolamos 200 MAbs contra DENV e ZIKV, e tamb&eacute;m isolamos 100 anticorpos monoclonais de indiv&iacute;duos infectados com Zika que j&aacute; haviam sido infectados pela Dengue. Muitos desses anticorpos neutralizaram o v&iacute;rus Zika &ndash; cinco em concentra&ccedil;&otilde;es muito baixas. Al&eacute;m disso, usamos um coquetel espec&iacute;fico de ZIKV de tr&ecirc;s desses MAbs neutralizantes mutados &ndash; SMZAb1, SMZAb2 e SMZAb5 &ndash; para prevenir com sucesso a infec&ccedil;&atilde;o por Zika em primatas n&atilde;o humanos. Outros experimentos demonstraram que um desses anticorpos, o SMZAb2, administrado isoladamente, preveniu a infec&ccedil;&atilde;o pelo ZIKV.

Saber Mais:&nbsp;<a href="https://www.science.org/doi/10.1126/scitranslmed.aan8184">https://www.science.org/doi/10.1126/scitranslmed.aan8184</a>

Our long-term goal is to use a cocktail of neutralizing monoclonal antibodies (MAbs) to prevent and treat DENV and ZIKV infection in at-risk populations, thereby reducing virus-induced morbidity, transmission, and the possibility of severe consequences after infection occurs.

Nosso objetivo de longo prazo é usar um coquetel de anticorpos monoclonais neutralizantes (MAbs) para prevenir e tratar a infecção por Dengue (DENV) e Zika (ZIKV) em populações de risco, reduzindo assim a morbidade induzida pelo vírus, a transmissão e a possibilidade de consequências graves após a ocorrência da infecção.

More about the project

MIssão

Aplicação de anticorpos monoclonais (nmAbs) para tratamento e controle de surtos.

Deploying neutralizing monoclonal antibodies for prevention, treatment, and outbreak ring-fencing.

His resumé speaks for itself: Professor of Pathology and Director of Translational Research at George Washington School of Medicine and Health Sciences in Washington DC, and a former faculty member of Harvard Medical School, the University of Wisconsin-Madison School of Medicine and Public Health, and the University of Miami Miller School of Medicine. David Watkins, Member of the Scientific Committee of Global Pandemic Shield, is also a fellow in the American Academy of Microbiology, and a recipient of the Elizabeth Glaser Scientist Award.

GPS Talks | How to Unleash The Power of Science

Taking an unprecedented step last week, São Paulo-based technology and impact laboratory Sthorm presented its newest initiative to the world: Global Pandemic Shield (GPS). The introduction took place in one of the crypto sector's most prestigious events, the Blockchain Central UNGA of the United Nations General Assembly in New York.

GPS - UN General Assembly Presentation

It was during the COVID-19 crises that Esper Kallás became a reference for authorities, governments and the media on the combat against the Covid-19 pandemic. Since the early 1990s, Esper also is a global public health reference for his brilliant studies of HIV infection and other infectious diseases, focusing on the areas of immunopathology, treatment and prevention. Kallás has several projects financed, both by national and international development agencies.

subtítulo do video

Esper Kallás and the decentralization of science

One of Latin America's most important researchers in radiology and diagnostic imaging, Giovanni Guido Cerri is a Professor of Radiology at FMUSP; President of the Councils of the Institutes of Radiology (InRad) and Innovation (InovaHC) at the Hospital das Clínicas at FMUSP; and both a full standing member and board member of the National Academy of Medicine.

GPS Talks | How Science Funding and Digital Technologies Can Prevent Future Pandemics

Primeiro tratamento contra a Febre Amarela

First Yellow Fever treatment

We have isolated several potent neutralizing monoclonal antibody (nMAbs) that reduce viral replication in the Syrian hamster model of YF virus infection. We plan to move these nMAbs along the developmental pipeline to create Master Cell Banks and then to test them in clinical trials. We will develop a cocktail or a single antibody that can prevent death in patients with wtYF or YF vaccine-induced viscerotropic disease.

Isolamos v&aacute;rios anticorpos monoclonais neutralizantes potentes que reduziram, no modelo de hamster s&iacute;rio, a replica&ccedil;&atilde;o viral de infec&ccedil;&atilde;o por Febre Amarela. Planejamos agora mover esses anticorpos para criar um reposit&oacute;rio de c&eacute;lulas-matriz e depois test&aacute;-las em ensaios cl&iacute;nicos. Vamos desenvolver um coquetel ou um &uacute;nico anticorpo que pode prevenir a morte em pacientes com wtYF ou doen&ccedil;a viscerotr&oacute;pica induzida pela vacina.

Our goal is to deploy antibodies for the treatment of wild type yellow fever (wtYF), to ring-fence wtYF outbreaks that continue to occur in Africa and South America despite vaccination. This intervention can also be applied to prevent wtYF among at risk patients who have contraindications to the yellow fever (YF) vaccine, and to treat the rare but potential lethal YF vaccine-induced viscerotropic disease.

Nosso objetivo é aplicar anticorpos para o tratamento da Febre Amarela do tipo selvagem (wtYF), e ainda conter os surtos que continuam a ocorrer na África e  América do Sul, apesar da vacinação. Essa intervenção pode também ser aplicada para prevenir wtYF dentre pacientes de risco que tenham  contra-indicações quanto ao uso de vacina de febre amarela, e para tratar a rara mas potencialmente letal doença viscerotrópica induzida pela vacina.

Desenvolvimento de nmAbs

The World Health Organization (WHO) estimates an annual YF incidence of 200,000 cases, with 29,000 to 60,000 related deaths. Currently, there is no treatment for wtYF infection. Even though numerous vaccine campaigns have been mounted, immunization coverage remains heterogenous, resulting in a significant number of at-risk individuals with the potential for international spread. We identified and tested potent YF-specific neutralizing monoclonal antibodies using rodents and non-human primate models. The administration of these antibodies during acute pathogenic YF infection was able to prevent severe disease and death.

Read More:&nbsp;<a href="https://www.google.com/url?q=https://www.biorxiv.org/content/10.1101/2022.05.16.491863v1&amp;sa=D&amp;source=docs&amp;ust=1663166385694218&amp;usg=AOvVaw2fVlIuSqoRsXTYv4kELOSv">https://www.biorxiv.org/content/10.1101/2022.05.16.491863v1</a>

A Organiza&ccedil;&atilde;o Mundial da Sa&uacute;de (OMS) estima uma incid&ecirc;ncia anual de 200.000 casos de Febre Amarela, com um n&uacute;mero de mortes entre 29.000 e 60.000. Atualmente, n&atilde;o h&aacute; tratamento para a infec&ccedil;&atilde;o por wtYF. Apesar de in&uacute;meras campanhas vacinais terem sido organizadas, a cobertura de imuniza&ccedil;&atilde;o permanece heterog&ecirc;nea, resultando em um n&uacute;mero significativo de indiv&iacute;duos em risco, com potencial de dissemina&ccedil;&atilde;o internacional. N&oacute;s identificamos e testamos potentes anticorpos neutralizantes espec&iacute;ficos contra Febre Amarela, empregando modelos de roedores e primatas n&atilde;o humanos. A administra&ccedil;&atilde;o desses anticorpos, durante&nbsp; a fase patog&ecirc;nica aguda da infec&ccedil;&atilde;o, foi capaz de prevenir doen&ccedil;a grave e morte.

Saber Mais:&nbsp;<a href="https://www.google.com/url?q=https://www.biorxiv.org/content/10.1101/2022.05.16.491863v1&amp;sa=D&amp;source=docs&amp;ust=1663166385694218&amp;usg=AOvVaw2fVlIuSqoRsXTYv4kELOSv">https://www.biorxiv.org/content/10.1101/2022.05.16.491863v1</a>

Vacinação

Um programa inédito que prepara o mundo para outras pandemias.

A new anticipatory pandemic preparedness program and repository.

NIAID advances the understanding, diagnosis, and treatment of many of the world&rsquo;s most intractable and widespread diseases. Key research areas include newly emerging and re-emerging infectious diseases.

O Centro de Pesquisa de Vacinas (VRC) &eacute; uma divis&atilde;o intramural do Instituto Nacional de Alergia e Doen&ccedil;as Infecciosas (NIAID), parte dos Institutos Nacionais de Sa&uacute;de (NIH), Departamento de Sa&uacute;de e Servi&ccedil;os Humanos dos EUA (HHS). A miss&atilde;o do VRC &eacute; descobrir e desenvolver de vacinas a produtos &agrave; base de anticorpos que endere&ccedil;am m&uacute;ltiplas doen&ccedil;as infecciosas.

NIH - NIAID

NIAID Vaccine Research Center

Centro de Pesquisa de Vacinas NIAID

Um novo programa de preparação contra pandemias

A new anticipatory pandemic preparedness program and repository

Through a network of investigators and collaborators, PREMISE will conduct virologic and immunologic screening of targeted and broad cohorts to detect reactivity against viruses of pandemic potential.

Por meio de uma rede de pesquisadores e colaboradores, Projeto Premise realizar&aacute; triagem virol&oacute;gica e imunol&oacute;gica de amplos grupos de pessoas para detectar reatividade contra v&iacute;rus de potencial pand&ecirc;mico.

PREMISE will serve as a translational vehicle to integrate serologic and cellular immune discovery, targeting a broad array of pathogens, into product development, accelerating the global response to pandemic threats.

Projeto Premise servirá como um veículo translacional para integrar a descoberta imunológica sorológica e celular, visando um amplo espectro de patógenos, no desenvolvimento de produtos, acelerando a resposta global às ameaças pandêmicas.

mission

missão

PREMISE will also sequence samples from zoonotic reservoirs and symptomatic humans for virus identification. The resulting analyses will be shared to pre-emptively generate reagent and data resources for early detection and diagnosis, and to identify monoclonal antibodies and immunogens for vaccine discovery and development.

Projeto Premise tamb&eacute;m sequenciar&aacute; amostras de reservat&oacute;rios zoon&oacute;ticos e humanos sintom&aacute;ticos para identifica&ccedil;&atilde;o de v&iacute;rus. As an&aacute;lises resultantes ser&atilde;o compartilhadas para gerar preventivamente reagentes e dados para detec&ccedil;&atilde;o e diagn&oacute;stico precoces, e ainda para identificar anticorpos monoclonais e imun&oacute;genos para descoberta e desenvolvimento de vacinas.

&nbsp;

Albums

Featured creators

Explore all NFTs()

Garden#9

Garden#9

The Girl and The Fox

The Girl and The Fox

Pablo Picasso

Pablo Picasso

Caravaggio

Caravaggio

Universo em Crise

Universo em Crise

Colorful Bird

Colorful Bird

Seratonina

Seratonina

Estruturas de transformação

Estruturas de transformação